CytoDyn Earnings Call Transcripts
Fiscal Year 2026
-
Leronlimab is advancing through phase II trials in colorectal cancer, with rapid enrollment and promising early ctDNA and tumor response data. Retrospective results in triple-negative breast cancer are strong, and new studies are planned. Large market opportunities and regulatory milestones are targeted in 2024.
-
The CLOVER Phase II study in metastatic colorectal cancer shows promising early results, with all patients experiencing ctDNA declines and most achieving tumor shrinkage or stable disease. Leronlimab showed a strong safety profile and potential efficacy, even in KRAS-mutant cases. Upcoming milestones include expanded access in breast cancer and new trials.
Fiscal Year 2025
-
Lorazumab is advancing in clinical trials for solid tumors, with strong safety and promising efficacy data, especially in triple-negative breast cancer. Market opportunities are significant, and regulatory progress includes Fast Track status for TNBC. Financial strategies and expanded access programs are underway.
Fiscal Year 2024
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals preliminarily approved. Final voting results will be reported in the meeting minutes and a Form 8-K filing.